Reviparin

DB09259

small molecule approved investigational

Deskripsi

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.A32019 It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.A32021 It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.L1469

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

860 Data
Apixaban Apixaban may increase the anticoagulant activities of Reviparin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Reviparin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reviparin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Reviparin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Reviparin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reviparin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Obinutuzumab.
Rivaroxaban Reviparin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Reviparin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reviparin.
Urokinase Urokinase may increase the anticoagulant activities of Reviparin.
Vitamin E Vitamin E may increase the anticoagulant activities of Reviparin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Reviparin.
Trandolaprilat The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Reviparin.
Moexiprilat The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Reviparin.
Cilazaprilat The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Reviparin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Reviparin.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Reviparin.
Quinine The therapeutic efficacy of Reviparin can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Reviparin can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Reviparin.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Reviparin.
Corticorelin ovine triflutate The risk or severity of hypotension and sinus node depression can be increased when Reviparin is combined with Corticorelin ovine triflutate.
Oritavancin The therapeutic efficacy of Reviparin can be decreased when used in combination with Oritavancin.
Streptokinase Streptokinase may increase the anticoagulant activities of Reviparin.
Telavancin The therapeutic efficacy of Reviparin can be decreased when used in combination with Telavancin.
Palifermin The serum concentration of Palifermin can be increased when it is combined with Reviparin.
Pentoxifylline The therapeutic efficacy of Reviparin can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Reviparin.
Levocarnitine The therapeutic efficacy of Reviparin can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Reviparin.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Reviparin.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Reviparin.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Reviparin.
Estriol Estriol may decrease the anticoagulant activities of Reviparin.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Reviparin.
Quinestrol Quinestrol may decrease the anticoagulant activities of Reviparin.
Hexestrol Hexestrol may decrease the anticoagulant activities of Reviparin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reviparin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reviparin.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Reviparin.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Reviparin.
Zeranol Zeranol may decrease the anticoagulant activities of Reviparin.
Equol Equol may decrease the anticoagulant activities of Reviparin.
Methallenestril Methallenestril may decrease the anticoagulant activities of Reviparin.
Epimestrol Epimestrol may decrease the anticoagulant activities of Reviparin.
Moxestrol Moxestrol may decrease the anticoagulant activities of Reviparin.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Reviparin.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Reviparin.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Reviparin.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Reviparin.
Biochanin A Biochanin A may decrease the anticoagulant activities of Reviparin.
Formononetin Formononetin may decrease the anticoagulant activities of Reviparin.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Reviparin.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Reviparin.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Reviparin.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reviparin.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Reviparin.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Reviparin.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Reviparin.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Reviparin.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Reviparin.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Reviparin.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Reviparin.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Reviparin.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Reviparin.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Reviparin.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reviparin.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Reviparin.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Reviparin.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Reviparin.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reviparin.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Reviparin.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Reviparin.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reviparin.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Reviparin.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Reviparin.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Reviparin.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Reviparin.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Reviparin.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Reviparin.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Reviparin.
Olsalazine The risk or severity of bleeding can be increased when Reviparin is combined with Olsalazine.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Reviparin.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Reviparin.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Reviparin.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8917255
    Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43.
  • PMID: 10759689
    Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul